Nuvalent Inc Cl A (NUVL)

$75.84 -0.15 (-0.20%)
Market Cap 5.40B
Revenue (ttm) 0.00
Net Income (ttm) -126.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 504,500
Avg Vol 456,266
Day's Range N/A - N/A
Shares Out 71.05M
Stochastic %K 52%
Beta 1.38
Analysts Strong Sell
Price Target $115.08

Latest News on NUVL

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

Jan 13, 2025, 6:30 AM EST - 4 days ago

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

Nuvalent: A Logical Acquisition Target

Jan 10, 2025, 1:22 PM EST - 7 days ago

Nuvalent: A Logical Acquisition Target

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 6:30 AM EST - 4 weeks ago

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nuvalent Appoints Grant Bogle to Board of Directors

Dec 9, 2024, 6:30 AM EST - 5 weeks ago

Nuvalent Appoints Grant Bogle to Board of Directors

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 6:52 AM EST - 7 weeks ago

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 6:30 AM EST - 2 months ago

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Sep 23, 2024, 12:34 PM EDT - 4 months ago

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

Sep 18, 2024, 4:05 PM EDT - 4 months ago

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases

Sep 17, 2024, 1:20 PM EDT - 4 months ago

Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Sep 16, 2024, 10:23 PM EDT - 4 months ago

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity

Sep 16, 2024, 1:44 PM EDT - 4 months ago

Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity

Cancer Biotech Nuvalent's Stock Jumps on Positive Data

Sep 16, 2024, 11:18 AM EDT - 4 months ago

Cancer Biotech Nuvalent's Stock Jumps on Positive Data

Nuvalent Announces Public Offering of Common Stock

Sep 16, 2024, 7:00 AM EDT - 4 months ago

Nuvalent Announces Public Offering of Common Stock

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Sep 14, 2024, 5:00 AM EDT - 4 months ago

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Sep 13, 2024, 9:53 AM EDT - 4 months ago

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

Sep 9, 2024, 6:30 AM EDT - 4 months ago

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 29, 2024, 6:30 AM EDT - 5 months ago

Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 6:30 AM EDT - 5 months ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results

Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor

Jul 22, 2024, 6:30 AM EDT - 6 months ago

Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor

Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024

Jul 16, 2024, 6:30 AM EDT - 6 months ago

Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024

Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer

Jul 11, 2024, 6:30 AM EDT - 6 months ago

Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Jun 24, 2024, 7:00 AM EDT - 7 months ago

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Nuvalent (NUVL) CEO On The Future Of Cancer Treatments

Jun 17, 2024, 12:19 PM EDT - 7 months ago

Nuvalent (NUVL) CEO On The Future Of Cancer Treatments

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Jun 14, 2024, 7:15 AM EDT - 7 months ago

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference

May 29, 2024, 6:30 AM EDT - 8 months ago

Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

May 16, 2024, 4:01 PM EDT - 8 months ago

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results

May 9, 2024, 6:30 AM EDT - 9 months ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024

Apr 8, 2024, 4:30 PM EDT - 10 months ago

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024

Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024

Mar 5, 2024, 4:52 PM EST - 11 months ago

Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 6:30 AM EST - 11 months ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520

Feb 27, 2024, 6:15 AM EST - 11 months ago

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Feb 26, 2024, 2:55 PM EST - 11 months ago

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors

Feb 12, 2024, 6:30 AM EST - 1 year ago

Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors

Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 1, 2024, 6:30 AM EST - 1 year ago

Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones

Jan 8, 2024, 6:30 AM EST - 1 year ago

Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones

Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 21, 2023, 6:30 AM EST - 1 year ago

Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results

Nov 14, 2023, 6:30 AM EST - 1 year ago

Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results

Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day

Nov 1, 2023, 6:30 AM EDT - 1 year ago

Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day

Nuvalent Announces Pricing of Public Offering of Common Stock

Oct 16, 2023, 9:55 PM EDT - 1 year ago

Nuvalent Announces Pricing of Public Offering of Common Stock

Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC

Oct 13, 2023, 6:30 AM EDT - 1 year ago

Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC

Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip

Oct 5, 2023, 11:00 AM EDT - 1 year ago

Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip

Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile

Oct 4, 2023, 12:21 PM EDT - 1 year ago

Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

Sep 18, 2023, 6:30 AM EDT - 1 year ago

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors

Sep 5, 2023, 6:30 AM EDT - 1 year ago

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors

Nuvalent to Participate in Upcoming September Investor Conferences

Aug 31, 2023, 6:30 AM EDT - 1 year ago

Nuvalent to Participate in Upcoming September Investor Conferences

Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results

Aug 10, 2023, 6:30 AM EDT - 1 year ago

Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results

Nuvalent to Participate in Upcoming August Investor Conferences

Aug 1, 2023, 6:30 AM EDT - 1 year ago

Nuvalent to Participate in Upcoming August Investor Conferences

Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

May 24, 2023, 6:30 AM EDT - 1 year ago

Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results

May 11, 2023, 6:30 AM EDT - 1 year ago

Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results

Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Apr 19, 2023, 6:30 AM EDT - 1 year ago

Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days